No quarterly revenue total was found in IMMIX BIOPHARMA, INC.'s SEC filings.
Immix Biopharma, Inc. (IMMX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$11.8 million. As of Jun 30, 2026 it held $234.2 million in cash and investments and $1.0 million in total debt.
Revenue
—
Net income
$-11.56M
-74.5% vs year-ago quarter
Operating cash flow
$-11.74M
-121.0% vs year-ago quarter
Free cash flow
$-11.76M
-116.2% vs year-ago quarter
EPS
$-0.18
+18.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
71.54M
+148.1% vs year-ago quarter
Net cash
$233.16M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1873835
- Former names
- Immix Biopharma, Inc. (until Oct 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$12.5M | -$10.8M | -$10.9M | -$7.7M | -$6.7M |
| Net income | -$11.6M | -$10.1M | -$10.6M | -$7.6M | -$6.6M |
| Diluted EPS | -$0.18 | -$0.18 | -$0.27 | -$0.24 | -$0.22 |
| Operating cash flow | -$11.7M | -$9.8M | -$11.0M | -$5.9M | -$5.3M |
| Free cash flow | -$11.8M | -$9.9M | -$11.2M | -$6.3M | -$5.4M |
| Total assets | $239.1M | $95.8M | $104.8M | $20.1M | $15.6M |
| Total liabilities | $10.2M | $11.5M | $11.0M | $11.8M | $11.0M |
| Stockholders' equity | $228.9M | $84.4M | — | — | — |
| Cash and investments | $234.2M | $90.6M | $100.4M | $15.9M | $11.6M |
| Total debt | $1.0M | $1.0M | $1.1M | $1.1M | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 22, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
All 244 Immix Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.